NCT04173793View on ClinicalTrials.gov

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

September 26, 2022

Study Completion Date

September 26, 2022

Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
DRUG

AK102

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

DRUG

Statins and/or Ezetimibe

Lipid-lowering therapies

Trial Locations (2)

100000

Peking Union Medical College Hospital, Beijing

100029

Beijing Anzhen Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

AD Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Akeso

INDUSTRY